Document:

Exhibit 10.1

 

EYEGATE PHARMACEUTICALS,
INC.

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT
AGREEMENT, entered into as of October 21, 2021 (this “Agreement”), is made by and between Bayon Therapeutics Pty Ltd, an
Australian proprietary company limited by shares (the “Employer”), EyeGate Pharmaceuticals, Inc., a Delaware corporation
(“EyeGate”), and Eric J. Daniels, MD, MBA (the “Employee”).

 

WHEREAS, the
Employer desires to employ the Employee and the Employee desires to be employed by the Employer, upon and subject to the terms set forth
in this Agreement;

 

NOW, THEREFORE,
in consideration of the premises and the mutual promises herein contained, the parties hereto hereby agree as follows:

 

1.            
Freedom to Contract. The Employee represents that he is free to enter into this Agreement, that he has not made
and will not make any agreements in conflict with this Agreement, and that he will not disclose to the Employer, or use for the Employer’s
benefit, any trade secrets or confidential information which is the property of any other party.

 

2.            
Employment. The Employer hereby employs the Employee, and the Employee hereby accepts his employment by the Employer,
subject to and upon the terms and conditions set forth herein.

 

3.            
Effective Date and Term. The effective time of this Agreement shall be as of October 21, 2021 (the “Effective
Date”) and such employment shall continue thereafter in full force and effect until terminated in accordance with the provisions
of this Agreement. The obligations and agreements of the Employee pursuant to Sections 8.7, 10.2, 10.3, 11 and 12 hereof shall survive
the termination of this Agreement for any reason.

 

4.            
Title and Duties; Extent of Services.

 

4.1             
The Employee shall promote the business and affairs of the Employer as Managing Director and Chief Development Officer. The Employee
shall also serve as Chief Development Officer of EyeGate. As Chief Development Officer of the Employer and EyeGate and Managing Director
of the Employer, the Employee shall have such duties and responsibilities as may be assigned to him by EyeGate’s President and
Chief Executive Officer and its Board of Directors (the “Board of Directors”) from time to time and such other duties and
responsibilities as are normal and customary for Chief Development Officers and Managing Directors. The Employee shall report and be
responsible to the Board of Directors. The Employee shall devote his best efforts and entire time, attention and energies to the business
and affairs of the Employer and EyeGate. Unless the Employee has received the approval of the Board of Directors, he shall not participate
in any other business or render services to any other business, as a principal, consultant, employee, or in any other capacity.

 

4.2              During
his employment, the Employee may serve on the board of directors, board of advisors, or other similar governing or advisory boards
of other companies, institutions, or organizations with the prior written consent of the Board of Directors (not to be unreasonably
withheld), provided that: (i) the Employee does not use proprietary, confidential and/or trade secret information, property, assets
or employees of the Employer or EyeGate in engaging in such activities; (ii) any such activities do not pose a conflict of interest
or interfere with the Employee’s duties to the Employer; and (iii) any such activities are not directly or indirectly for or
for the benefit of a business engaged in any commercial activity that is competitive with EyeGate or the Employer or otherwise in
breach of the Confidentiality Agreement. The Employer and EyeGate agree that the Employee may continue to serve on the board of
directors of Okogen, Inc. and the medical advisory board of Bimini Technologies subject to the preceding clauses (i) through
(iii).

 

    1

     

    

 

5.            
[Reserved]

 

6.            
Compliance with Policies. Employee acknowledges and agrees that compliance with Employer’s and EyeGate’s
policies, practices, and procedures is a term and condition of his employment under this Agreement.

 

7.             Location of Employment. Employee shall work out of Employee’s home office near Melbourne, Australia or shall
work at any other location mutually agreed upon by the Employer and the Employee, provided that Employee will be required to travel
regularly to EyeGate’s Massachusetts office or other locations, and elsewhere for business from time to time, consistent with the
Employer’s business needs.

 

8.             Compensation and Benefits.

 

8.1             
Salary. The Employer shall pay the Employee a salary at the rate of Forty-One Thousand Australian Dollars (AUD$41,000.00)
per month (which annualizes to Four Hundred Ninety-Two Thousand Australian Dollars (AUD$492,000.00)), payable bi-weekly in arrears or
otherwise in accordance with the Employer’s normal and customary payroll practices applicable to all of its employees. The amount
of salary payable by Employer pursuant to this Section 8.1 shall be inclusive of all superannuation entitlements (statutory or otherwise)
and subject to such deductions or amounts to be withheld as shall be required under applicable law or as lawfully requested by the Employee.

 

8.2             
Performance Bonus. The Employee shall be eligible to receive a performance bonus in respect of each fiscal year of the
Employer. Payment of any such performance bonus and the amount, if any, of any such performance bonus shall be entirely at the discretion
of the Board of Directors, with an annual target of up to forty percent (40%) of the Employee’s annual base salary. In determining
the amount of any performance bonus to be paid to Employee under this Section 8.2, the Board of Directors shall consider the extent to
which the performance criteria established between the Employee and the Board of Directors with respect to such fiscal year has been
achieved. In the event that the Board of Directors determines, in its discretion, to make payment of a performance bonus to Employee
pursuant to this Section 8.2, then Employer shall use best efforts to make payment of such performance bonus within sixty (60) calendar
days of the end of the applicable fiscal year of the Employer. Notwithstanding anything express or implied in this Section 8.2 to the
contrary, the Employee must remain an employee of the Employer on the date that the Employer makes payment of any performance bonus pursuant
to this Section 8.2 in order to receive any performance bonus.

 

    2

     

    

 

8.3             
 Medical Benefits. During the term of this Agreement, the Employer shall reimburse the Employee’s cost of private
family health insurance

 

8.4             
Sick Leave and Vacation. During the term of this Agreement, the Employee shall be entitled to paid sick leave and vacation
consistent with the Fair Work Act 2009 (Act) and the Employer’s policy concerning sick leave and vacation.

 

8.5             
Other Benefits. During the term of the Employee’s employment with the Employer pursuant to this Agreement, the Employee
shall be entitled to receive such other retirement, welfare and fringe benefits (“employee benefits”) as are provided by
the Employer to its senior executives and/or key employees, in each case in accordance with the terms and conditions set forth in the
plan, agreement or arrangement representing or evidencing such benefits.

 

8.6             
Discretionary Nature of Benefits. The Employee understands that the Employer may amend, change or cancel or terminate any
of its employment policies and “employee benefits” at any time as allowed by law or by any applicable plan, agreement or
arrangement representing or evidencing such employee benefits.

 

8.7             
Taxes. All compensation and benefits (including, without limitation, any superannuation, fringe benefits, bonuses, non-cash
compensation, subsidies, severance pay or benefits under Article 8 and Section 10.2 hereof) payable or to be provided to the Employee
shall be subject to all applicable withholding taxes, to applicable foreign, federal, state and local deductions, and to any other proper
deductions

 

9.             Stock
Options; Acceleration Upon Change of Control.

 

9.1             
The Employee shall be eligible for grants of stock options (the “Options”) under EyeGate’s 2014 Equity Incentive
Plan, as may be amended from time to time (the “Plan”), subject to the discretion of the Board of Directors. The Options
shall be incentive stock options to purchase shares of EyeGate’s common stock, USD$0.01 par value per share (the “Common
Stock”). The Options, if any, shall be subject to, and governed by, the terms and provisions of the Plan and stock option agreement(s)
granted thereunder (“Stock Option Agreements”).

 

9.2             
Subject to approval by the Compensation Committee of the Board of Directors, the Employee shall be granted Options
to purchase 50,000 shares of Common Stock, effective upon the Effective Date of this Agreement (the “Option Grant Date”).
  Such Options shall vest based on the Employee’s continued employment with the Employer as follows: (a) one-third (1/3) of
the shares subject such Options shall vest on the first anniversary of the Option Grant Date and (b) thereafter, one twenty-fourth (1/24)
of the remaining shares on the last day of each of the twenty-four (24) consecutive months commencing with the month next following the
first anniversary of the Option Grant Date.  Such Options shall, in all events, be subject to the terms of the Plan.

 

9.3              Upon
a Change of Control, all of the Employee’s then unvested stock options and/or restricted stock awards granted to the Employee
prior to such Change of Control under the Plan, including, but not limited to, all stock options granted pursuant to Section 9.2,
shall become fully vested and immediately exercisable, notwithstanding any vesting schedule or other provisions to the contrary in
the agreements evidencing such options or awards, and EyeGate and the Employee hereby agree that such stock option agreements and
restricted stock awards are hereby, and will be deemed to be, amended to give effect to this provision. For the purposes hereof, a
 “Change of Control” occurs upon (a) the closing of any merger or consolidation of EyeGate with any other unrelated
person or entity, or (b) the sale of all or substantially all of the assets of EyeGate to another unrelated person or entity, or (c)
the sale of more than fifty percent (50%) of the total fair market value or total voting power of the stock of EyeGate to an
unrelated party, such that, in each case, the transaction has been approved by EyeGate’s stockholders, and in which the
stockholders of EyeGate immediately prior to such merger, consolidation or sale shall, immediately after such merger, consolidation
or sale, own less than fifty percent (50%) of the issued and outstanding capital stock of the person or entity that is the surviving
company of any such merger or consolidation, or the acquirer in the case of any such sale of all or substantially all of the assets
of EyeGate. The provisions of this paragraph shall apply only if the Employee is the Managing Director and Chief Development Officer
of the Employer at the time of a Change of Control.

 

    3

     

    

 

10.           Termination.

 

10.1         
Termination Rights of the Parties. The Employee or the Employer may terminate the Employee’s employment at any time
by giving the other party thirty (30) calendar days’ prior written notice thereof, whereupon such employment shall terminate. The
date on which the Employee’s employment terminates hereunder is hereinafter referred to as the “Termination Date”.

 

10.2         
Employee’s Right to Compensation Following Termination; Severance Pay.

 

(a)               
If the Employee’s employment hereunder terminates for any reason whatsoever, the Employer
shall pay his (or, in the case of death, his estate) all accrued but unpaid base salary and vacation pay through and including the Termination
Date, which amounts shall be paid to the Employee (or his estate) in a lump sum as of such Termination Date. Subject to the terms and
conditions of this Agreement, the Employee shall also be entitled to such other benefits for which he is eligible under the terms and
conditions of the Employer’s employee benefit plans, stock options arrangements, and any applicable law. The accrued compensation
and benefits described in this Section 10.2(a) are collectively referred to as the “Accrued Benefits.”

 

(b)               
If (i) the Employee voluntarily terminates his employment hereunder without Good Reason (as defined
in Section 10.2(e) below) or (ii) the Employee’s employment hereunder terminates by reason of his death or disability or (iii)
the Employer terminates the employment of the Employee, at any time, for Cause, then, other than the Accrued Benefits, neither the Employee
nor his estate, heirs or other successors shall be entitled to severance pay or other benefits under this Agreement after the Termination
Date.

 

(c)                If
the employment of the Employee is terminated by the Employer for any reason other than for Cause (as defined in Section 10.2(e)
below) at any time or if the employment of the Employee is terminated by the Employee for Good Reason then, subject to Sections 10.3
and subsection (d) hereof, and in addition to the Accrued Benefits, the Employee shall be entitled to: (i) severance pay in the form
of a continuation of the periodic payment of his salary for a period of three (3) months from the Termination Date (provided
that such period shall be extended to a total of six (6) months if the Employee’s date of termination occurs on or after the
eighteen (18) month anniversary of the date of this Agreement or at any time following a Change of Control); and (ii) an amount
equal to the product of (A) the maximum performance bonus, pursuant to Section 8.2, that he would have been eligible to receive for
the year in which such termination occurs, multiplied by (B) 0.25 (provided that such multiple shall be increased to 0.5 if
the Employee’s date of termination occurs on or after the eighteen (18) month anniversary of the date of this Agreement or at
any time following a Change of Control), which shall be payable no later than the last installment of his severance. The continued
salary payments referred to in the foregoing clause (i) shall be made in accordance with the Employer’s standard payroll
practices and timing as in effect from time to time.

 

    4

     

    

 

(d)               
If the employment of the Employee is terminated by the Employer for any reason other than for Cause,
or if the employment of the Employee is terminated by the Employee for Good Reason at any time, continuation coverage under the Employer’s
private health and dental plans, then the Employer will subsidize the cost of such coverage for a period of three 3 months from the Termination
Date (provided that such period shall be extended to a total of six (6) months if the Employee’s date of termination occurs
on or after the eighteen (18) month anniversary of the date of this Agreement or at any time following a Change of Control)

 

(e)               
For purposes of this Agreement, “Cause” shall mean (i) the Employee’s willful
failure to perform his duties (other than any such failure resulting from incapacity due to physical or mental illness), (ii) the Employee’s
willful failure to comply with any valid directive of the Board of Directors, (iii) the Employee’s engagement in dishonesty, illegal
conduct, or serious misconduct, which is, in each case, materially injurious to the Employer, EyeGate or their respective affiliates,
(iv) the Employee’s embezzlement, misappropriation, or fraud, whether or not related to the Employee’s employment with the
Employer, (v) the Employee’s conviction or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law
equivalent) or a crime that constitutes a misdemeanor involving moral turpitude, (vi) the Employee’s material violation of the
Employer’s or EyeGate’s written policies or codes of conduct, or (vii) the Employee’s material breach of any material
obligation under this Agreement, the Confidentiality Agreement or any other written agreement between the Employee, on the one hand,
and the Employer and/or EyeGate, on the other hand. For the purposes of this Agreement, “Good Reason” shall mean (i) the
failure of the Employer to employ the Employee in his current position such that Employee’s duties, authority, or responsibilities
are materially diminished without the Employee’s consent; (ii) a material reduction in the Employee’s aggregate base salary
below the amount stipulated in Section 8.1 hereof without the Employee’s consent (unless such reduction is in connection with a
proportional reduction in compensation to all or substantially all of EyeGate’s officers); or (iii) a material breach by the Employer
or EyeGate of this Agreement. The Employee cannot terminate employment for Good Reason unless the Employee has provided written notice
to the Employer of the existence of the circumstances providing grounds for termination for Good Reason and the Employer has had at least
thirty (30) calendar days from the date on which such notice is provided to cure such circumstances.

 

(f)                 In
the event that the employment of the Employee is terminated by the Employer for any reason other than for Cause or in the event that
the Employee voluntarily terminates his employment hereunder for Good Reason, then that portion of the Employee’s then
unvested stock options and/or restricted stock awards granted to the Employee under any EyeGate stock option plan which would have
become vested over the three (3) month period following such termination (provided that such period shall be extended to a
total of six (6) months if the Employee’s date of termination occurs on or after the eighteen (18) month anniversary of the
date of this Agreement or at any time following a Change of Control) had the Employee continued as an employee of Employer
throughout such applicable period, shall, instead, become fully vested and immediately exercisable on the Termination Date,
notwithstanding any vesting schedule or other provisions to the contrary in the agreements evidencing such options or awards, and
EyeGate and the Employee hereby agree that such stock option agreements and restricted stock awards are hereby, and will be deemed
to be, amended to give effect to this provision.

 

    5

     

    

 

(g)               
The Employee hereby acknowledges and agrees that (i) he shall not be entitled to receive any compensation
or benefits from the Employer or EyeGate with respect to any period of time after the Termination Date except to the extent otherwise
expressly provided in this Section 10.2.; and (ii) EyeGate may set off any amounts the Employee owes EyeGate against any amounts
EyeGate owes the Employee at the date of termination except for amounts EyeGate is not entitled by law to set off.

 

10.3         
Employee Release. Any obligation of the Employer to provide the Employee severance payments or other benefits under this
Agreement is expressly conditioned upon the Employee reviewing and signing (and not revoking during any applicable revocation period)
a general release of claims in a form reasonably satisfactory to the Employer (the “Release”). The Employer shall provide
the Employee with the Release promptly after the date on which the Employee gives or receives, as the case may be, notice of termination
of the Employee’s employment. Payment of all severance payment or other benefits to which the Employee may be entitled after the
Termination Date, other than the Accrued Benefits, shall commence after the effective date of the Release, as set forth in the Release.
To the extent that the Release’s effective date occurs after severance payments or other benefits may become due under Section 10.2
hereof, the payments that have accumulated between the Termination Date and before the Release’s effective date will be paid in
a lump sum in the first payment made after the Release’s effective date.

 

11.           Proprietary
Information, Inventions and Non-Solicitation Agreement. The Employee hereby acknowledges that he has entered into EyeGate’s
standard form of Proprietary Information, Inventions and Non-Solicitation Agreement (the “Confidentiality Agreement”), which
is incorporated herein as if reproduced in its entirety. By accepting this Agreement, the Employee hereby ratifies and accepts the terms
of the Employee Proprietary Information, Inventions and Non-Solicitation Agreement.

 

12.           Unique Nature of Agreement; Specific Enforcement. The Employer, EyeGate and the Employee agree and acknowledge that
the rights and obligations set forth with this Agreement are of a unique and special nature and that the Employer is, therefore, without
an adequate legal remedy in the event of the Employee’s violation of any of the covenants set forth in this Agreement. The Employer,
EyeGate and the Employee agree, therefore, that each of the covenants made by the Employee under this Agreement shall be specifically
enforceable in equity, without the need to post a bond or provide other security, in addition to all other rights and remedies, at law
or in equity or otherwise (including termination of employment), that may be available to the Employer or EyeGate.

 

    6

     

    

 

13.           Miscellaneous.

 

13.1         
Entire Agreement. This Agreement, the Confidentiality Agreement, and the Stock Option Agreements shall represent the entire
agreement of the parties with respect to the arrangements contemplated hereby. No prior agreement, whether written or oral, shall be
construed to change, amend, alter, repeal or invalidate this Agreement. This Agreement may be amended only by a written instrument executed
in one or more counterparts by the parties.

 

13.2         
Waiver. No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed
or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other obligations
hereunder. Failure on the part of either party to complain of any act or failure to act of the other party or to declare the other party
in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver hereunder shall
be effective unless it is in writing, executed by the party waiving the breach or default hereunder.

 

13.3         
Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto, their respective successors
and assigns and, in the case of the Employee, his heirs. This Agreement may be assigned by the Employer to any Affiliate of the Employer
and to a successor of its business (whether by purchase or otherwise). “Affiliate of the Employer” means any person which,
directly or indirectly, controls or is controlled by, or is under common control with, the Employer and, for the purposes of this definition,
 “control” (including the terms “controlled by” and “under common control with”) shall mean the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of another, whether through the
ownership of voting securities, the holding of office in another, by contract, or otherwise. The Employee may not assign or transfer
any or all of her rights or obligations under this Agreement.

 

13.4         
Disputes. In case of any dispute hereunder, the parties will submit to the exclusive jurisdiction and venue of any court
of competent jurisdiction sitting in Suffolk County, Massachusetts, and will comply with all requirements necessary to give such court
jurisdiction over the parties and the controversy. Each party waives any right to a jury trial.

 

13.5         
Severability. All headings and subdivisions of this Agreement are for reference only and shall not affect its interpretation.
In the event that any provision of this Agreement should be held unenforceable by a court of competent jurisdiction, such court is hereby
authorized to amend such provision so as to be enforceable to the fullest extent permitted by law, and all remaining provisions shall
continue in full force without being impaired or invalidated in any way.

 

13.6         
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of The Commonwealth of Massachusetts.
All disputes or claims shall be brought in the state or federal courts located in Suffolk County Massachusetts and each party waives
its jurisdictional rights to other venues and to any defenses based on jurisdiction.

 

Remainder of
page left intentionally blank

 

    7

     

    

 

IN WITNESS WHEREOF, the Employer, EyeGate
and the Employee have executed this Agreement as of the date first set forth above.

 

	Employer:	 
	 	 
	BAYON THERAPEUTICS PTY LTD	 
	 	 
	By:	/s/ Brian M. Strem, Ph.D.	 
	Name:	Brian M. Strem, Ph.D.	 
	Title:	Director	 
	 	 
	EyeGate:	 
	 	 
	EYEGATE PHARMACEUTICALS, INC.	 
	 	 
	By:	 /s/ Brian M. Strem, Ph.D.	 
	Name:	 Brian M. Strem, Ph.D.	 
	Title:	President and Chief Executive Officer	 
	 	 
	Employee:	 
	 	 
	/s/ Eric J. Daniels, MD, MBA	 
	Eric J. Daniels, MD, MBA	 

 

    8Document

                                                            Exhibit 10.1

CONSULTING AGREEMENT

            This CONSULTING AGREEMENT (the “Agreement”), is made as of October 25, 2021 by and among STABILIS SOLUTIONS, INC., a Florida corporation having its principal address at 11750 Katy Freeway, Suite 900, Houston, TX 77079 (the “Company”), ENATEK SERVICES, LLC with an address at 3225 McLeod Drive, Suite 100 (the “Consultant”) and JAMES G. AIVALIS with an address of 22406 Caroline Cove, Katy, TX 77450 (“Aivalis”).  The Company, the Consultant and Aivalis are referred to collectively herein as the “Parties” and individually as a “Party”.

                                                                 RECITALS:

            The Company and Aivalis are parties to an Executive Employment Agreement dated March 11, 2020, as amended effective February 1, 2021 and April 1, 2021 (the “Amended Executive Employment Agreement”). The employment of Aivalis as an executive employee under the Amended Executive Employment Agreement was terminated by Aivalis’ retirement as of January 31, 2021 at which time Aivalis began providing post-employment services to the Company as a consultant and member of the Board of Directors through January 31, 2022 pursuant to the provisions of Section 10(b) of the Amendment #1 of Amended Executive Employment Agreement; and 
            
            The Company, the Consultant and Aivalis have agreed to enter into this Agreement to set forth the sole and exclusive terms under which the services of Aivalis as a consultant will be provided to the Company by the Consultant effective as of February 1, 2022 (the “Effective Date”).

             NOW, THEREFORE, the Parties hereto agree as follows:

            1. Consulting Services. 

            As of the Effective Date Consultant shall provide the services of Aivalis to the Company to advise the Company CEO and the Board of Directors concerning LNG including market information as an independent consultant and advisor. Consultant shall make Aivalis available upon reasonable notice given by the Company to consult with and advise the Company on such matters.  Such services shall include service of Aivalis as a non-independent member of the Board of Directors of the Company and any committee thereof if elected or appointed to the Board and committees thereof for no additional compensation. 
               

2. Consulting Term.

            Aivalis shall be available to provide the consulting and advisory services set forth in Section 1 above for a period commencing on the Effective Date and ending on January 31, 2023.

            3. Consulting Fee and Benefits.

            a. As compensation for Aivalis’ consulting and advisory services during the Consulting Term, the Company shall pay the Consultant at the rate of $12,500 per month by the 10th day of each month during the Consulting Term. Consultant shall be responsible for all income tax withholding, FICA and Medicare payments due Consultant and Aivalis, it being understood that in providing such services Consultant and Aivalis shall be acting as an independent contractor and not as an employee or agent of the Company. 

            b. Consultant shall be entitled to reimbursement for reasonable business and travel expenses incurred by Aivalis in the performance of his duties in accordance with the Company’s normal reimbursement practices. 
            c. During the Consulting Term, Consultant shall have the option of continuing participation of Aivalis in the Company’s health insurance plan benefits as in effect from time to time during the Consulting Period. The Company shall pay a portion of the costs thereof which shall be considered as additional compensation hereunder.             
4. Termination of the Consulting Term.

            The Consultant may terminate the Consulting Term with the Company hereunder, with or without cause, upon thirty (30) days’ advance written notice to the Company.   The Company may terminate the Consulting Term with the Consultant hereunder, in the event Consultant is unable or unwilling to provide the Consulting Services (the “Cause”). Prior to termination of the Consulting Term the Company will give twenty (20) days’ notice to the Consultant of such termination and the Cause therefor. Such termination shall be ineffective if Consultant reasonably cures such Cause   within thirty (30) days’ after receipt of the Company’s notice.
5. Continuing Obligations of Consultant and Aivalis. 
Consultant and Aivalis shall fully comply with the applicable restrictive covenants of Sections 11-12 of the Amended Executive Employment Agreement and the Company’s Business Ethics and Conduct Policy. 

6.  Notices.  
2

All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given upon receipt by the Parties at the addresses set forth above (or at such other address for a Party as shall be specified by like notice):

7.  Counterparts; Facsimile Execution
.  
This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties.  Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.
8.  Entire Agreement
.  
This Agreement and all other agreements, exhibits, and schedules referred to in this Agreement constitute(s) the final, complete, and exclusive statement of the terms of the agreement between the parties pertaining to the subject matter of this Agreement and supersedes all prior and contemporaneous understandings or agreements of the parties.  This Agreement may not be contradicted by evidence of any prior or contemporaneous statements or agreements.  No party has been induced to enter into this Agreement by, nor is any party relying on, any representation, understanding, agreement, commitment or warranty outside those expressly set forth in this Agreement. 
9.  Governing Law
; Arbitration of Disputes. 
This Agreement shall be governed by, and construed in accordance with, the laws of the State of Texas, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. Any controversy or claim arising out or relating to this Agreement shall be settled exclusively by arbitration by a single arbitrator in Harris County, Texas administered by the American Arbitration Association under its Commercial Arbitration Rules and judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.  
10.  Assignment
.  
To the fullest extent permitted by law, neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by operation of law or otherwise by any of the Parties without the prior written consent of the other Parties.  Any purported assignment without such consent shall be void.  Subject to the preceding sentences, this Agreement 
3

will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and assigns.
The Parties hereto have executed and delivered this Consulting Agreement as of the date first above written.
The Company:
Stabilis Solutions, Inc.
By:     _______________________________
    Westy Ballard
    President and Chief Executive Officer

Aivalis:
_____________________________________
James G. Aivalis, 
an individual

Consultant:
Enatek Services, LLC
By:     ________________________________
    James G. Aivalis,
    Manager

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]